Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Active not recruiting 5Withdrawn 3Recruiting 2Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 2Hematologic Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × tazemetostat × Clear all
NCT05205252 2023-08-15

ARIA

Ipsen

Phase 1/2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT05604417 2023-07-07

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Massachusetts General Hospital

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular

NCT05152459 2023-05-31

Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

City of Hope Medical Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡